WeVote
Log In

Bill

Bill

HR 8339

Drug Origin Transparency Act of 2026

119th Congress Introduced by Dan Crenshaw and 3 co-sponsors

The act requires drug labels and reports to reveal original manufacturers and all supply-chain suppliers for APIs, with detailed origin data and more frequent reporting.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 8339

Summary of HR 8339 — Drug Origin Transparency Act of 2026

Purpose and intent

HR 8339, introduced in the 119th Congress, seeks to increase transparency around drug manufacturing origins and supply chains. By amending the Federal Food, Drug, and Cosmetic Act (FDCA), the bill aims to enhance reporting on drug manufacturing inputs and require labeling that identifies original manufacturers and supply-chain points. The overall goal is to improve visibility into where drugs and their active pharmaceutical ingredients (APIs) come from, potentially reducing supply-chain risk and increasing accountability.

Key provisions

1) Enhanced reporting of drug manufacturing amounts (Section 2)

  • Amends FDCA Section 510(j)(3) to add a new subparagraph (C) requiring each report under the existing reporting framework (A) to include:
    • Information about the drug’s supply chain, including the identity of suppliers for each API, API intermediate, and in-process material used in manufacture, preparation, propagation, or processing.
    • The respective amounts of the drug produced or processed using each identified supplier’s API or other materials.
  • Reporting frequency must be more often than annually, with a maximum cadence of up to four times per year (as specified by the Secretary in regulations or guidance).
  • Additional information that may be required by regulation or guidance can be included in these reports, with the earliest compliance date being six months after finalization of the implementing regulation or guidance. If no regulation/guidance is issued, reporting remains required as described.

2) Structural conformity and terminology (Section 2)

  • Recasts existing reference to “subparagraph (A)” to align with the newly added subparagraph (C), ensuring consistency in reporting requirements.

3) Drug labeling to disclose original manufacturer and supply chain (Section 3)

  • Amends FDCA Section 502 to require labeling on drugs (including APIs) to include:
    • The name and place of business of the original manufacturer of the drug or API.
    • The name and place of business of any subsequent manufacturer (if different from the original), and the packer or distributor.
    • For APIs, the certificate of analysis must likewise include the original manufacturer’s name and location.
  • The Secretary may establish regulations allowing reasonable variations in labeling implementation, including electronic labeling or alternate placement.
  • New labeling requirements apply unless regulations provide for reasonable variations in implementation.

Who is affected

  • Drug manufacturers, including both finished drug products and APIs, will face expanded reporting obligations and labeling requirements.
  • Suppliers and manufacturers (APIs, intermediates, in-process materials) may need to disclose identities and origins in reporting.
  • Regulators (FDA) would issue implementing regulations and guidance to specify the exact data fields, formats, and reporting schedules.
  • Labeling stakeholders would need to ensure product labels and certificates of analysis reflect the original manufacturer and supply-chain information.

Procedural and timeline notes

  • The bill was introduced on April 16, 2026, and referred to the House Committee on Energy and Commerce.
  • Compliance timelines depend on final regulations or guidance to be issued by the Secretary, with certain elements requiring action within six months after final guidance.
  • The act is titled the Drug Origin Transparency Act of 2026.

Potential impact

  • Increased visibility into drug supply chains could improve traceability and accountability.
  • Could affect international and domestic manufacturers, potentially impacting labeling formats and data reporting systems.
  • May inform policy discussions on drug safety, counterfeit risk, and resilience of pharmaceutical supply chains.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.